Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 3
2006 2
2007 3
2009 3
2010 6
2011 7
2012 9
2013 13
2014 13
2015 9
2016 13
2017 11
2018 12
2019 6
2020 11
2021 14
2022 13
2023 19
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Fleischmann R, et al. Among authors: yamaoka k. Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12. Ann Rheum Dis. 2023. PMID: 37308218 Free PMC article. Clinical Trial.
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gómez-Reino JJ. Curtis JR, et al. Among authors: yamaoka k. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5. Ann Rheum Dis. 2023. PMID: 36600185 Free PMC article. Clinical Trial.
Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission.
Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, Ando T, Nakayama Y, Okuzono Y, Takiguchi M, Kurisu R, Miyazaki T, Yoshimoto K, Yasuoka H, Yamaoka K, Morita R, Yoshimura A, Toyoshiba H, Takeuchi T. Tasaki S, et al. Among authors: yamaoka k. Nat Commun. 2018 Jul 16;9(1):2755. doi: 10.1038/s41467-018-05044-4. Nat Commun. 2018. PMID: 30013029 Free PMC article.
JAK inhibitors in rheumatology.
Yamaoka K, Oku K. Yamaoka K, et al. Immunol Med. 2023 Sep;46(3):143-152. doi: 10.1080/25785826.2023.2172808. Epub 2023 Feb 6. Immunol Med. 2023. PMID: 36744577 Review.
Safety of jakinibs: lessons from ORAL Surveillance.
Bukhari M, Bergman M, Giles JT, Lozada C, Cush J, Yamaoka K, McKay C, Kavanaugh A. Bukhari M, et al. Among authors: yamaoka k. Rheumatology (Oxford). 2022 Nov 2;61(11):4223-4225. doi: 10.1093/rheumatology/keac166. Rheumatology (Oxford). 2022. PMID: 35323916 No abstract available.
143 results